Compare Hims and Hers Health Inc (HIMS) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nutrien Ltd — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 5.1× Hims and Hers Health Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Nutrien Ltd for 59 Days on average.
| HIMS | NTR | |
|---|---|---|
Market Cap | $6.55B | $33.31B |
Volume | 14,842,814 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $62.76 | $83.94 |
52-Week Low | $14.52 | $53.64 |
Typical Hold Time | 21 Days | 59 Days |
Enterprise Value | $7.25B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
Nutrien (NTR) trades at $69.87, down 0.14% with a bearish technical signal despite positive analyst sentiment. The company shows improving fundamentals with 2025 revenue of $26.89B and net income of $2.27B, representing an 8.44% margin. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates. Cash flow trends indicate operational strength with $4.01B from operations in 2025, though net cash flow remains negative. The stock faces headwinds from fertilizer industry challenges but benefits from strong potash demand and cost discipline.
NTR presents a moderate buy opportunity with 60.61% analyst buy ratings and $76.14 consensus price target offering 9% upside. Key catalysts include November 2026 Investor Day and structural gas arbitrage benefits, while risks involve fertilizer price volatility, geopolitical supply disruptions, and sulfur cost pressures. The company's North American nitrogen assets provide competitive advantage, but investors should monitor agricultural cycle trends and input cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
